{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:08:05Z","timestamp":1791554885025,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Foundation of CSCO-Shiyao","award":["Y-SY201901-0068"],"award-info":[{"award-number":["Y-SY201901-0068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03618-x","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T06:02:25Z","timestamp":1721800945000},"page":"542-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors"],"prefix":"10.1007","volume":"27","author":[{"given":"Han","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0570","authenticated-orcid":false,"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"1","key":"3618_CR1","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1038\/s41467-022-33170-7","volume":"13","author":"Z Xin","year":"2022","unstructured":"Xin Z, et al. The immune landscape of human thymic epithelial tumors. Nat Commun. 2022;13(1):5463.","journal-title":"Nat Commun"},{"issue":"2","key":"3618_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.rcl.2020.11.006","volume":"59","author":"MFK Benveniste","year":"2021","unstructured":"Benveniste MFK, et al. Thymic epithelial neoplasms: tumor-node-metastasis staging. Radiol Clin North Am. 2021;59(2):183\u201392.","journal-title":"Radiol Clin North Am"},{"issue":"12","key":"3618_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jtho.2022.08.008","volume":"17","author":"Y He","year":"2022","unstructured":"He Y, et al. A knock-in mouse model of thymoma with the GTF2I L424H mutation. J Thorac Oncol. 2022;17(12):1375\u201386.","journal-title":"J Thorac Oncol"},{"key":"3618_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1183\/16000617.0174-2022","volume":"32","author":"DW Dumoulin","year":"2023","unstructured":"Dumoulin DW, et al. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. Eur Respir Rev. 2023;32:167.","journal-title":"Eur Respir Rev"},{"issue":"11","key":"3618_CR5","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","volume":"13","author":"VC du Merveilleux","year":"2018","unstructured":"du Merveilleux VC, et al. Systemic Therapy in advanced thymic epithelial\u00a0tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13(11):1762\u201370.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3618_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","volume":"10","author":"HS Kim","year":"2015","unstructured":"Kim HS, et al. A prospective phase II study of cisplatin and cremophor EL-free paclitaxel (Genexol-PM) in patients with unresectable thymic epithelial tumors. J Thorac Oncol. 2015;10(12):1800\u20136.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3618_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","volume":"18","author":"HA Jung","year":"2023","unstructured":"Jung HA, et al. A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). J Thorac Oncol. 2023;18(2):223\u201331.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3618_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174\u201389.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3618_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599\u2013608.","journal-title":"Ann Oncol"},{"issue":"4","key":"3618_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3618_CR11","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.7150\/jca.40500","volume":"12","author":"YL Wang","year":"2021","unstructured":"Wang YL, et al. Expression of PD1\/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment. J Cancer. 2021;12(6):1698\u2013707.","journal-title":"J Cancer"},{"issue":"3","key":"3618_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.euf.2015.03.004","volume":"1","author":"AS McDaniel","year":"2016","unstructured":"McDaniel AS, et al. Expression of PDL1 (B7\u2013H1) Before and after neoadjuvant chemotherapy in urothelial carcinoma. Eur Urol Focus. 2016;1(3):265\u20138.","journal-title":"Eur Urol Focus"},{"key":"3618_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers13051065","volume":"13","author":"K Kaira","year":"2021","unstructured":"Kaira K, Imai H, Kagamu H. Perspective of immune checkpoint inhibitors in thymic carcinoma. Cancers (Basel). 2021;13:5.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3618_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jclinpath-2017-204788","volume":"71","author":"EK Bagir","year":"2018","unstructured":"Bagir EK, et al. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. J Clin Pathol. 2018;71(7):637\u201341.","journal-title":"J Clin Pathol"},{"issue":"6","key":"3618_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/modpathol.2017.6","volume":"30","author":"A Weissferdt","year":"2017","unstructured":"Weissferdt A, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017;30(6):826\u201333.","journal-title":"Mod Pathol"},{"issue":"1","key":"3618_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12916-022-02361-w","volume":"20","author":"Z Song","year":"2022","unstructured":"Song Z, et al. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial. BMC Med. 2022;20(1):154.","journal-title":"BMC Med"},{"key":"3618_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms21239056","volume":"21","author":"V Tateo","year":"2020","unstructured":"Tateo V, et al. Immunobiology of thymic epithelial tumors: implications for immunotherapy with immune checkpoint inhibitors. Int J Mol Sci. 2020;21:23.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3618_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/13543784.2022.2113373","volume":"31","author":"F Conforti","year":"2022","unstructured":"Conforti F, et al. Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2022;31(9):895\u2013904.","journal-title":"Expert Opin Investig Drugs"},{"key":"3618_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","volume":"174","author":"W Wang","year":"2022","unstructured":"Wang W, et al. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study. Eur J Cancer. 2022;174:21\u201330.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3618_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","volume":"10","author":"SK Padda","year":"2015","unstructured":"Padda SK, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10(3):500\u20138.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"3618_CR21","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","volume":"22","author":"S Yokoyama","year":"2016","unstructured":"Yokoyama S, et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma. Clin Cancer Res. 2016;22(18):4727\u201334.","journal-title":"Clin Cancer Res"},{"key":"3618_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362: k3529.","journal-title":"BMJ"},{"issue":"10","key":"3618_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S1470-2045(22)00558-7","volume":"23","author":"Y Shintani","year":"2022","unstructured":"Shintani Y, Funaki S. New combination therapy for thymic epithelial tumours. Lancet Oncol. 2022;23(10):1237\u20139.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3618_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","volume":"15","author":"J Remon","year":"2020","unstructured":"Remon J, et al. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. 2020;15(6):914\u201347.","journal-title":"J Thorac Oncol"},{"key":"3618_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","volume":"99","author":"Y Katsuya","year":"2016","unstructured":"Katsuya Y, et al. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer. 2016;99:4\u201310.","journal-title":"Lung Cancer"},{"issue":"1","key":"3618_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","volume":"22","author":"YQ Ao","year":"2023","unstructured":"Ao YQ, et al. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Mol Cancer. 2023;22(1):70.","journal-title":"Mol Cancer"},{"key":"3618_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, et al. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer. 2023;180:117\u201324.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3618_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"3618_CR29","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1002\/cam4.5357","volume":"12","author":"Y Hao","year":"2023","unstructured":"Hao Y, et al. Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients. Cancer Med. 2023;12(5):5649\u201355.","journal-title":"Cancer Med"},{"issue":"13","key":"3618_CR30","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-3338","volume":"77","author":"LM Colli","year":"2017","unstructured":"Colli LM, et al. Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. 2017;77(13):3666\u201371.","journal-title":"Cancer Res"},{"key":"3618_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107324","volume":"184","author":"V Yeung","year":"2023","unstructured":"Yeung V, et al. High levels of expression of Trop-2 in thymic epithelial tumors. Lung Cancer. 2023;184: 107324.","journal-title":"Lung Cancer"},{"issue":"8","key":"3618_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","volume":"11","author":"AT Alberobello","year":"2016","unstructured":"Alberobello AT, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11(8):1345\u201356.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3618_CR33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41416-021-01658-6","volume":"126","author":"V Chen","year":"2022","unstructured":"Chen V, et al. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine. Br J Cancer. 2022;126(5):754\u201363.","journal-title":"Br J Cancer"},{"issue":"8","key":"3618_CR34","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-10-1689","volume":"17","author":"M Breinig","year":"2011","unstructured":"Breinig M, et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res. 2011;17(8):2237\u201349.","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1007\/s12094-024-03794-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03618-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:22:10Z","timestamp":1738254130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03618-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03618-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12094-024-03794-w","asserted-by":"object"}]},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the corresponding author name Zhengbo Song.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-024-03794-w","URL":"https:\/\/doi.org\/10.1007\/s12094-024-03794-w","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2022-63). Individual consent for this retrospective analysis was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}